Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 3,500 shares, an increase of 169.2% from the May 15th total of 1,300 shares. Based on an average daily volume of 4,500 shares, the short-interest ratio is presently 0.8 days. Currently, 0.0% of the shares of the company are short sold.

Pharming Group Price Performance

Shares of NASDAQ PHAR traded up $0.55 during trading hours on Monday, hitting $11.30. 5,054 shares of the stock were exchanged, compared to its average volume of 6,233. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company has a market cap of $768.55 million, a PE ratio of -43.45 and a beta of 0.02. The company's fifty day simple moving average is $9.70 and its two-hundred day simple moving average is $9.20. Pharming Group has a 1-year low of $6.65 and a 1-year high of $12.61.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The business had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. On average, sell-side analysts predict that Pharming Group will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Oppenheimer increased their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.